Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Non-Current Liabilities: 2016-2025

Historic Total Non-Current Liabilities for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $317.3 million.

  • Akebia Therapeutics' Total Non-Current Liabilities rose 25.51% to $317.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $317.3 million, marking a year-over-year increase of 25.51%. This contributed to the annual value of $264.7 million for FY2024, which is 0.48% up from last year.
  • Akebia Therapeutics' Total Non-Current Liabilities amounted to $317.3 million in Q3 2025, which was up 5.01% from $302.2 million recorded in Q2 2025.
  • Akebia Therapeutics' Total Non-Current Liabilities' 5-year high stood at $436.1 million during Q1 2022, with a 5-year trough of $246.0 million in Q1 2024.
  • Over the past 3 years, Akebia Therapeutics' median Total Non-Current Liabilities value was $264.7 million (recorded in 2024), while the average stood at $271.3 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Total Non-Current Liabilities slumped by 35.04% in 2023, and later increased by 25.51% in 2025.
  • Akebia Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $371.1 million in 2021, then declined by 9.71% to $335.1 million in 2022, then dropped by 21.40% to $263.4 million in 2023, then increased by 0.48% to $264.7 million in 2024, then rose by 25.51% to $317.3 million in 2025.
  • Its last three reported values are $317.3 million in Q3 2025, $302.2 million for Q2 2025, and $278.4 million during Q1 2025.